Cargando…

1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)

BACKGROUND: Mab is a MDR nontuberculous mycobacterium that causes lung infections in patients with structural lung disease. Mab harbors a chromosomally encoded class A β-lactamase, Bla(Mab), able to hydrolyze penicillins, cephalosporins and carbapenems. L,D- and D,D-transpeptidases (L,D TP and D,D T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dousa, Khalid M, Kurz, Sebastian G, Bethel, Christopher, Miller, Alita, Bonomo, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777676/ http://dx.doi.org/10.1093/ofid/ofaa439.1822

Ejemplares similares

Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action
por: Dousa, Khalid M., et al.
Publicado: (2022)

Eradicating Pulmonary Mycobacterium abscessus: The Promise of Dual β-Lactam Therapy
por: Alahmdi, Bayan, et al.
Publicado: (2023)

1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
por: Dousa, Khalid M, et al.
Publicado: (2019)

1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
por: Nguyen, David, et al.
Publicado: (2021)

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021)

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023)

2806. The Mechanism of β-Lactam Antibiotic Action: Structural Analysis of Mycobacterium abscessus l,d-Transpeptidases, d,d-Carboxypeptidase and penicillin-binding-proteins binding by imipenem, ceftaroline, and amoxicillin
por: Shin, Eunjeong, et al.
Publicado: (2023)

1572. Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium abscessus
por: Dousa, Khalid M, et al.
Publicado: (2020)

Glby, Encoded by MAB_3167c, Is Required for In Vivo Growth of Mycobacteroides abscessus and Exhibits Mild β-Lactamase Activity
por: Galanis, Christos, et al.
Publicado: (2022)

803. Overcoming β-Lactam Resistance in Mycobacterium abscessus
por: Story-Roller, Elizabeth, et al.
Publicado: (2018)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection?
por: Dousa, Khalid M, et al.
Publicado: (2018)

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro
por: Pandey, R., et al.
Publicado: (2019)

85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
por: Miller, Alita, et al.
Publicado: (2023)

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium
por: Laure, Nana Nguefang, et al.
Publicado: (2022)

Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities
por: Story-Roller, Elizabeth, et al.
Publicado: (2018)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
por: Lickliter, Jason D., et al.
Publicado: (2020)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus
por: Lindman, Marissa, et al.
Publicado: (2019)

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa
por: Haines, Robbie R., et al.
Publicado: (2022)

2526. Ex Vivo Assessment of Sulbactam-Durlobactam (SUL-DUR) Clearance during Continuous Renal Replacement Therapy (CRRT)
por: Abouelhassan, Yasmeen, et al.
Publicado: (2023)

A 40-Year-Old Female With Mycobacterium abscessus Successfully Treated With a Dual Beta-Lactam Combination
por: Moguillansky, Natalia, et al.
Publicado: (2023)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

Newton: 1642-1727
por: Westfall, Richard S
Publicado: (1994)

Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
por: Martin, Juan F., et al.
Publicado: (2022)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Time-resolved β-lactam cleavage by L1 metallo-β-lactamase
por: Wilamowski, M., et al.
Publicado: (2022)

Synthesis and biological evaluation of novel β-lactam-metallo β-lactamase inhibitors
por: Shungube, Mbongeni, et al.
Publicado: (2023)

Interactions of hydrolyzed β-lactams with the L1 metallo-β-lactamase: Crystallography supports stereoselective binding of cephem/carbapenem products
por: Hinchliffe, Philip, et al.
Publicado: (2023)

The in vitro effect of new combinations of carbapenem–β-lactamase inhibitors for Mycobacterium abscessus
por: Fröberg, Gabrielle, et al.
Publicado: (2023)

The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics
por: Kim, Si Won, et al.
Publicado: (2020)

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia
por: Lin, Wei-Ting, et al.
Publicado: (2019)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease
por: Negatu, Dereje A., et al.
Publicado: (2022)

β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar
por: Sid Ahmed, Mazen A., et al.
Publicado: (2020)

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
por: Watkins, Richard R., et al.
Publicado: (2013)

Chemiluminescence Detection of Hydrogen Sulfide Release by β-Lactamase-Catalyzed β-Lactam Biodegradation: Unprecedented Pathway for Monitoring β-Lactam Antibiotic Bacterial Resistance
por: Gholap, Sachin Popat, et al.
Publicado: (2021)

Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities
por: Singhal, Neelja, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_15bknagb6hc6nnchk9tmp29qbi